Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
Stock Information for Berkeley Lights Inc.
Loading
Please wait while we load your information from QuoteMedia.
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.